Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), today announced positive results from its Phase 2 study of oral, once-daily VTX3232 in patients with Obesity and Cardiovascular Risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback